Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DRIVE-SHIFT: Switch to MK-1439A in HIV-1
NCT02397096Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2015
- Primary completion
- Feb 2018
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of doravirine in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Merck & Co. Primary endpoint: Percentage of Participants Maintaining HIV-1 RNA <50 Copies/mL at 48 weeks. Started Jun 2015; status: completed.
02
Drugs
doravirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02397096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02397096.